StockData
Intuitive Surgical Inc logo

Intuitive Surgical Inc (ISRG) operating KPIs

ISRGNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 21, 2026Score 17/3023% above fair value
$432.01−16.75 (-3.73%)

Close on Oct 30, 2026Market cap $152.62BP/E 49.5Yield –

KPIs

Operating metrics that drive Intuitive Surgical's business · fiscal year ends December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q3 2026
2026-09-30
Q2 2026
2026-06-30
Q1 2026
2026-03-31
Q4 2025
2025-12-31
Q3 2025
2025-09-30
Q2 2025
2025-06-30
Q1 2025
2025-03-31
Q4 2024
2024-12-31
Q3 2024
2024-09-30
Q2 2024
2024-06-30
Q1 2024
2024-03-31
Q4 2023
2023-12-31
Total da Vinci Surgical Procedures Worldwide (Thousands)(M)5
906889847849797775732725613
Total da Vinci Procedures — Reported YoY Growth (%)(%)
14.0%15.0%16.0%17.0%19.0%17.0%17.0%
Combined Worldwide Procedures (da Vinci + Ion) — Reported YoY Growth (%)(%)
15.0%16.0%17.0%18.0%20.0%
U.S. da Vinci Surgical Procedures (Thousands)(M)1
559552528544507495465
U.S. da Vinci Procedures — Reported YoY Growth (%)(%)
10.0%12.0%14.0%16.0%14.0%13.0%
Outside U.S. (OUS) da Vinci Surgical Procedures (Thousands)(M)1
347337319304290280267
OUS da Vinci Procedures — Reported YoY Growth (%)(%)
20.0%20.0%19.0%24.0%23.0%24.0%
da Vinci SP Single-Port Procedures — Reported YoY Growth (%)(%)
55.0%68.0%78.0%91.0%88.0%81.0%70.0%74.0%60.0%58.0%
Ion Endoluminal Lung Biopsy Procedures Performed1
49,70047,90042,70040,20037,90035,30030,700
Ion Endoluminal Biopsy Procedures — Reported YoY Growth (%)(%)
31.0%36.0%39.0%44.0%52.0%52.0%58.0%73.0%82.0%90.0%
da Vinci Surgical System Installed Base — Worldwide Total6
12,09411,71011,39511,10610,76310,48810,1899,9029,5399,2038,8878,606
U.S. da Vinci Installed Base
6,8076,6156,4776,3645,8075,111
Europe da Vinci Installed Base
2,4362,3252,2572,1681,8671,617
Asia da Vinci Installed Base
2,1762,1112,0491,9931,7451,484
Rest of World da Vinci Installed Base
675659612581483394
da Vinci SP Single-Port Installed Base
487445410377343314291273243222201177
da Vinci Installed Base under Operating Lease Arrangements — Total2
3,5553,4253,3253,2103,1152,9872,9062,7992,227
Fixed-Payment Operating Lease Installed Base (da Vinci)
1,5811,5221,4771,4001,3791,3011,3081,3071,204
Usage-Based Operating Lease Installed Base (da Vinci)
1,9741,9031,8481,8101,7361,6861,5981,4921,023
Ion Endoluminal System Installed Base — Worldwide Total1
1,1521,0961,041995954905853805736678604534
Ion Installed Base under Operating Lease Arrangements — Total2
411397380360362358334319214
Fixed-Payment Operating Lease Installed Base (Ion)
10911011211012312712412696
Usage-Based Operating Lease Installed Base (Ion)
302287268250239231210193118
da Vinci Surgical Systems Placed — Worldwide Total6
546468431532427395367493172413415
da Vinci 5 Fifth-Generation Systems Placed
315246232303240180147174110708
da Vinci SP Single-Port Systems Placed
4234353023193021212419
U.S. da Vinci System Placements
335267226304263216204284219149148209
Outside U.S. (OUS) da Vinci System Placements3
211201205228164179163209160192165206
Europe da Vinci System Placements
115791171186373888965718471
Asia da Vinci System Placements
7875628860695296749556110
Other Markets da Vinci System Placements
184726224137232421262525
da Vinci Unit Placements Involving Trade-In Transactions
15014411914614183676251
da Vinci System Placements under All Leasing Arrangements2
303264256262243199208
da Vinci System Placements under Operating Lease Arrangements3
291254243250231193198
Fixed-Payment Operating Lease Placements (da Vinci)
13112312510011669918292
Usage-Based Operating Lease Placements (da Vinci)
160131118150115124107140109
Operating Lease Share of Total da Vinci Placements (%)(%)
53.0%54.0%56.0%54.0%49.0%54.0%
da Vinci System Placements under Sales-Type Lease Arrangements
1210131212610
Ion Endoluminal Systems Placed — Worldwide Total3
565552425054496944
U.S. Ion System Placements
44423936414745
Outside U.S. (OUS) Ion System Placements3
1213136974
Europe Ion System Placements
10995
Asia Ion System Placements
1221
Other Markets Ion System Placements
1220
Ion System Placements under All Leasing Arrangements2
Ion System Placements under Operating Lease Arrangements3
26313616173429
Fixed-Payment Operating Lease Placements (Ion)
1,5811,5221,47751,3791,3011,3082414
Usage-Based Operating Lease Placements (Ion)
1,974171,848111,736211,5981415
Operating Lease Share of Total Ion Placements (%)(%)
46.0%56.0%69.0%34.0%63.0%59.0%
Ion System Placements under Sales-Type Lease Arrangements
22055
da Vinci Surgical System Average Selling Price — ASP ($M)($M)
1.611.591.741.681.601.501.621.591.511.441.381.42
da Vinci Instruments & Accessories (I&A) Revenue per Procedure ($)($)1
1,8601,8801,8501,8001,8001,8601,8001,8001,7801,800
Ion Endoluminal I&A Revenue per Procedure ($)($)
2,2002,200
Total Recurring Revenue (I&A, Services & Operating Leases) ($M)($M)1
2,5552,4692,3702,3232,1382,0791,926
Recurring Revenue as % of Total Revenue (%)(%)
84.0%85.0%86.0%81.0%85.0%85.0%85.0%80.0%82.0%
Operating Lease Revenue Recognized ($M)($M)3
275262250242223214195182168157148139
Variable (Usage-Based) Operating Lease Revenue ($M)($M)
1781691571511381301121018780.17063.1
Sales-Type Lease Revenue Recognized ($M)($M)
25.320.832.724.830.915.126.574.530.245.113.323.9
Revenue from Customer Purchases of Leased Systems (Lease Buyouts) ($M)($M)
45565139223039
Remaining Performance Obligations (RPO — Unsatisfied Contract Revenue) ($M)($M)3
3,8003,4003,3003,0002,8802,8102,6702,6202,5202,3702,3402,290
Revenue Recognized from Beginning Contract Liability Balance ($M)($M)
971472344491126198348111818924
Contract Assets ($M)($M)
33.827.220.315.318.220.919.913.917.716.717.420.2
Contract Liabilities — Total ($M)($M)2
669662664598571572560523486477488492
Deferred Revenue — Current ($M)($M)
541549560507491500496469426434438446
Deferred Revenue — Non-Current ($M)($M)
12811310491.479.471.863.654.159.643.550.245.6
Foreign-Currency-Denominated Revenue as % of Total Revenue (%)(%)
27.0%27.0%29.0%24.0%26.0%25.0%
Total Consolidated Revenue ($M)($M)6
3,0492,8922,7712,8662,5052,4402,2532,4142,0382,0101,8911,928
Instruments & Accessories Revenue — Worldwide ($M)2
Instruments & Accessories Revenue — U.S. ($M)($M)
1,2481,1801,1221,1601,0621,0179641,008905891822819
Instruments & Accessories Revenue — Outside U.S. (OUS) ($M)($M)
550555565498457457404404359353337324
Systems Revenue — Worldwide ($M)2
Systems Revenue — U.S. ($M)($M)
506442380494398354336420265224213238
Systems Revenue — Outside U.S. (OUS) ($M)($M)
264243271292193221187234180224206242
Services Revenue — Worldwide ($M)2
Services Revenue — U.S. ($M)($M)
310311282276258258239224209204204199
Services Revenue — Outside U.S. (OUS) ($M)($M)
173162152146138133125123120114110106
Total Product Revenue (Instruments & Accessories + Systems) ($M)($M)
2,5672,4202,3372,4442,1092,0491,8902,0661,7091,6931,5771,624
Total U.S. Revenue ($M)($M)1
2,0631,9331,7831,9311,7181,6291,5381,6521,3791,3191,2391,256
U.S. Share of Total Revenue (%)(%)
68.0%67.0%64.0%69.0%67.0%68.0%68.0%66.0%66.0%
Total Outside U.S. (OUS) Revenue ($M)($M)1
986959988936788811715761659691652672
Outside U.S. (OUS) Share of Total Revenue (%)(%)
32.0%33.0%36.0%31.0%33.0%32.0%32.0%34.0%34.0%
Product Gross Profit ($M)($M)1
1,7691,6431,5571,4101,3631,220
Product Gross Profit Margin (%)(%)
68.9%67.9%66.6%66.8%66.5%64.5%
Service Gross Profit ($M)($M)1
316318273253255238
Service Gross Profit Margin (%)(%)
65.4%67.2%63.0%63.8%65.3%65.6%
Non-GAAP Gross Profit ($M)($M)2
2,1302,0241,8791,9421,7041,6571,4971,6781,4081,4061,2791,311
Non-GAAP Gross Profit Margin (%)(%)
69.9%70.0%67.8%67.6%68.0%67.9%66.4%
GAAP Gross Profit Margin (%)(%)
68.4%67.8%66.1%66.0%66.4%66.3%64.7%
Non-GAAP Income from Operations ($M)($M)
1,2701,2181,0771,070976947768928755754630621
Non-GAAP Net Income Attributable to Intuitive Surgical, Inc. ($M)($M)1
1,0551,002901914867798662805669641541574
Non-GAAP Diluted Net Income per Share ($)(€)
32.802.502.532.402.191.812.211.841.781.501.60
Share-Based Compensation Expense — Total Recognized ($M)($M)4
216213213207206200190180176176156152
Share-Based Compensation — Total Cost of Revenue ($M)($M)2
38.53838.637.640.338.938.435.332.831.229.730
Share-Based Compensation — Cost of Product Revenue ($M)($M)
28.428.829.328.731.530.330.227.324.923.622.723.1
Share-Based Compensation — Cost of Service Revenue ($M)($M)
10.19.209.308.908.808.608.2087.907.6076.90
Share-Based Compensation — Research & Development ($M)($M)
87.786.78279.877.674.76965.965.465.657.754.1
Share-Based Compensation — Selling, General & Administrative ($M)($M)
89.588.192.789.888.186.382.379.177.679.668.268.2
Income Tax Benefit Recognized for Share-Based Compensation ($M)($M)
434342.742.542.539.33732.936.936.132.432.2
Total Inventories, Net ($M)($M)3
2,1282,0291,9451,8401,7821,6671,5541,4871,4821,3841,2991,221
Raw Materials Inventory ($M)($M)
652608591561531525550564523484470455
Work-in-Process Inventory ($M)($M)
333332307288225231230206215183181160
Finished Goods Inventory ($M)($M)
1,1431,0881,0479911,026911774718744718648606
Accounts Receivable, Net ($M)($M)3
1,7211,6731,5961,5271,2601,2691,2221,2251,1531,1091,1281,130
Trade Accounts Receivable, Net ($M)($M)
1,4721,4331,3911,3581,1201,1321,0911,1179851,0031,0291,042
Unbilled Accounts Receivable ($M)($M)
278269237196165160155139192124116105
Reserve for Sales Returns ($M)($M)
28.528.932.726.724.922.92430.523.617.916.217
Net Investment in Sales-Type Leases — Total ($M)($M)7
331337366303330338358380350354344372
Gross Sales-Type Lease Receivables ($M)($M)
358368397318345352372393363366357385
Deferred Profit / Unearned Income on Sales-Type Leases ($M)($M)
27.130.430.914.714.813.714.213.912.712.812.212.9
Current Portion of Net Investment in Sales-Type Leases ($M)($M)
104102116101124125128131137134133137
Sales-Type Lease Net Investment — High Internal Credit Quality ($M)($M)
154149192160175174175184161179179201
Sales-Type Lease Net Investment — Moderate Internal Credit Quality ($M)($M)
175185170136147154176189183164156160
Sales-Type Lease Net Investment — Low Internal Credit Quality ($M)($M)
2.602.904.207.408.509.906.805.705.8011.29.4010.6
Undiscounted Future Sales-Type Lease Payments Receivable — Total ($M)($M)4
358368397318345352372393363366357385
Property, Plant & Equipment, Net ($M)($M)2
5,6765,5525,4485,3425,1514,9854,7994,6474,4334,1173,8003,538
Capital Expenditures Incurred but Not Yet Paid ($M)($M)
13.33.6065.2-9.305.10-2397.8-11810.76.3017818.5
U.S. Share of Total Long-Lived Assets (%)(%)
80.0%80.0%81.0%81.0%81.0%83.0%
Goodwill ($M)($M)1
558581613370348349348348348348348349
Intangible Assets, Net ($M)($M)5
19719817417.123
Finite-Lived Intangibles, Net — Customer Relationships ($M)($M)
1751801441.102.103.203.9056.207.108.209.60
Finite-Lived Intangibles, Net — Distribution Rights ($M)($M)
4.905.2015.60000.100.100.300.601.101.60
Finite-Lived Intangibles, Net — Technology-Based ($M)($M)
11.26.508.201012.414.715.617.918.82124.527.9
Indefinite-Lived IPR&D Intangible Assets ($M)($M)
66660
Amortization Expense of Intangible Assets ($M)($M)
9.30247.103.303.303.203.403.103.5055.105.10
Common Stock Repurchased — Total Value ($M)($M)3
2,9403791,1282001,9201810000066.3
Common Stock Repurchased — Shares (Millions)(M)
7.800.902.300.4040.30000000.20
Weighted-Average Share Repurchase Price ($)(€)
3774394904805180000
Remaining Share Repurchase Authorization ($M)($M)
1,8004,7006001,7001,9003,8001,1001,1001,1001,1001,1001,100
Income Before Taxes — Consolidated ($M)($M)
6681,055940956855832669810671655539516
Intuitive-Fosun Joint Venture (China, 40% NCI) — Net Income (Loss) Attributable to Noncontrolling Interest ($M)($M)1
1.605.104.504.704.805.805.302.305.504.602.504.50
Intuitive-Fosun Joint Venture (China, 40% NCI) — Noncontrolling Interest Equity Balance ($M)($M)
13212912311811210710195.994.288.283.889.7
ab medica / Abex / Excelencia Robótica Acquisition (Italy, Spain & Portugal) — Purchase Consideration ($M)4
ab medica / Abex Acquisition — Goodwill Recognized ($M)($M)
196
ab medica / Abex Acquisition — Intangible Assets Recognized ($M)($M)
281
ab medica / Abex Acquisition — Property, Plant & Equipment Acquired ($M)($M)
60.6
ab medica / Abex Acquisition — Net Assets Acquired ($M)($M)
550
Antitrust Class Action Litigation Settlement Charge ($M)($M)1
4500
Accrued Antitrust Litigation Settlement Liability ($M)($M)
450
Intuitive Surgical — FDA 510(k) Premarket Clearances Granted3
4144105248312
U.S. MedTech Industry Total — FDA 510(k) Premarket Clearances
855923756806797886736856767793713877
Intuitive Surgical — FDA Premarket Approvals (PMA & Supplements)
000000000000
U.S. MedTech Industry Total — FDA Premarket Approvals (PMA & Supplements)
565608567525585588524683538550459656
Intuitive Surgical — FDA MAUDE Medical Device Adverse Event Reports (Total)5
9,78410,71220,20210,23911,98316,01012,2873,9563,5623,3563,0962,870
Intuitive Surgical — FDA MAUDE Device Malfunction Reports
8,8569,88719,4919,52111,34815,31111,7303,1862,9132,7472,5552,289
Intuitive Surgical — FDA MAUDE Patient Injury Reports
812793677678597658532729609584523552
Intuitive Surgical — FDA MAUDE Death Reports
403234393739233839221626
U.S. MedTech Industry Total — FDA MAUDE Adverse Event Reports
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
Intuitive Surgical — FDA Medical Device Recalls
14111004001101
ClinicalTrials.gov — Cumulative Registered Clinical Studies (Intuitive Surgical)1
ClinicalTrials.gov — New Studies Started in Period
22111131123
U.S. Producer Price Index (PPI) — Surgical & Medical Instrument Manufacturing (PCU339112339112)(×)2
163.40162.90161.70159.60157.80156.90157.10155.20154.40154.10153.60151.00
U.S. PPI — Surgical Appliance & Supplies Manufacturing (PCU339113339113)(×)
269.30263.80253.80251.40249.60249.50248.70245.40245.10243.70240.10238.50
U.S. PPI — Electromedical & Electrotherapeutic Apparatus Manufacturing (PCU334510334510)(×)
92.8092.1092.0091.6090.7090.3090.1089.5089.3088.4088.3087.80
U.S. Consumer Price Index (CPI-U) — Medical Care Services (CUSR0000SAM2)(×)2
654.70650.90647.60638.40630.60623.40619.60613.00611.40605.80597.90
U.S. CPI-U — Medical Care Commodities (CUSR0000SAM1)(×)
404.90410.40416.80417.00416.50416.00412.60415.90414.50408.30410.10
U.S. Census Bureau QSS — U.S. Hospitals Quarterly Revenue (REV622TAXABL144QNSA) ($M)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Total Revenue ($M)($M)2
3,0492,8922,7712,8662,5052,4402,2532,4142,0382,0101,8911,928
Segment Revenue — Total Product ($M)($M)
2,5672,4202,3372,4442,1092,0491,8902,0661,7091,6931,5771,624
Gross Profit ($M)($M)
2,0841,9601,8311,9041,6621,6181,4581,6421,3741,3731,2451,277
Operating Income ($M)($M)3
593972855864760743578735577567469450
Total Operating Expenses ($M)($M)
1,4929899751,040903875880907797805776827
Research & Development Expense ($M)($M)
408371362353329313316295286280285260
Selling, General & Administrative Expense ($M)($M)
633618613687573561563613511525492567
Net Income Attributable to Intuitive Surgical, Inc. ($M)($M)8
523818822795704658698686565527545606
Interest & Other Non-Operating Income, Net ($M)($M)
75.882.785.191.395.588.790.474.993.787.269.165.7
Income Before Taxes ($M)($M)
6681,055940956855832669810671655539516
Income Tax Expense ($M)($M)
144231114156146168-35.2122100123-8.90-94.8
Net Income (Loss) Attributable to Noncontrolling Interest ($M)($M)
1.605.104.504.704.805.805.302.305.504.602.504.50
Basic Earnings per Share ($)(€)
1.502.312.311.981.841.951.591.481.54
Diluted Earnings per Share ($)(€)
1.492.292.281.951.811.921.561.461.51
Weighted-Average Basic Shares (Millions)(M)
349354355357359358356355354
Weighted-Average Diluted Shares (Millions)(M)
352357360362364365363361361
Total Assets ($M)2
Cash & Cash Equivalents ($M)($M)
2,9782,7602,0073,3682,8073,4472,6172,0622,4463,0672,8672,770
Prepaid Expenses & Other Current Assets ($M)($M)
536625752477575483371385349404405314
Operating Cash Flow ($M)($M)2
1,2241,061912893841715582823707621265228
Capital Expenditures ($M)($M)
113113103163105155117312248309242436
Investing Cash Flow ($M)($M)
1,898-26.6-915-209401261214-1,264-1,413-467-129-1,044

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core KPI Drivers (Groups 1–4): Surgical & diagnostic procedure volumes (da Vinci by region & clinical specialty, Ion endoluminal lung biopsy, da Vinci SP growth), Installed Base by platform/region/lease model, System Placements by generation/console/region/lease model, and Unit Economics (System ASP, I&A revenue per procedure, Recurring Revenue, Operating vs. Sales-Type Lease revenue, Lease Buyouts & RPO).
  • Standalone / Parent-Only Assessment (Step 3 & Step 4): Intuitive Surgical, Inc. files under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary & JV operations are instead captured directly from explicit disclosures in Group 10: Intuitive-Fosun Joint Venture in China (40% noncontrolling interest net income & equity) and the European direct distribution acquisition of ab medica, Abex & Excelencia Robótica (closed March 2, 2026).
  • Period Splitting (Step 4): Q4 values for 10-K/10-Q cumulative tables and cash flow statement quarters (Q2–Q4) are derived strictly via FY − 9M or YTD − prior YTD.

Not shown because recent periods are missing (13)

  • Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — U.S. Federal ($M)
  • Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — U.S. State ($M)
  • Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — Switzerland ($M)
  • Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — Other Foreign Jurisdictions ($M)
  • Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M)
  • Cumulative Peer-Reviewed Scientific Articles Referencing Intuitive Technologies (21,000+ to 43,000+) — Disclosed as lower-bound floor ('21,000+', '24,000+', '29,000+', '34,000+', '38,000+', 'more than 43,000') in ESG Reports 2019–2024; excluded per Step 5 rule against bound/floor figures.
  • New Peer-Reviewed Scientific Articles Published in Year (2,800+ to 4,000+) — Disclosed as lower-bound floor ('2,800+', '3,000+', '3,700+', '3,300+', '4,000+') in ESG Reports 2019–2024; excluded per Step 5 rule against bound/floor figures.
  • Cumulative Surgeons Trained on da Vinci Systems in U.S. & OUS (32,800+ to 89,500+) — Disclosed as lower-bound floor ('32,800+', '35,000+', '40,400+', '76,000+') in ESG Reports 2019–2023; excluded per Step 5 rule against bound/floor figures.
  • Active Patents Granted (2,900+ to 5,400) & Pending Patent Applications (1,900+ to 2,500) — Disclosed as lower-bound floor ('2,900+', '3,400+', '4,200+', '4,300+', '4,800+') in ESG Reports 2019–2023; excluded per Step 5 rule against bound/floor figures.
  • Cumulative da Vinci Procedures Performed Since Inception (7.2M+ to 16.94M+) — Disclosed as lower-bound floor ('7.2 million+', '8.5 million+', '10 million+', '14.2 million+', 'nearly 17 million') in ESG & Annual Reports; excluded per Step 5 rule against bound/floor figures.
  • Global Training Sessions (6,500+ to 9,000+), Active Proctors (1,000+ to 1,400+) & Portal Users (4,100+ to 17,000+) — Disclosed with '+' floor modifier in ESG Reports 2021–2023; excluded per Step 5 rule against bound/floor figures.
  • System Service Uptime (>99%) & QMS / Compliance Training Completion Rate (>98%) — Disclosed with '>' inequality modifier ('>99%', '>98%', '>88%') in ESG Reports 2021–2023; excluded per Step 5 rule against bound/floor figures.
  • Quarterly da Vinci System Placements in Japan & China (Earnings Call Transcripts) — Disclosed in Q1 2026 and Q3 2023–Q4 2025 earnings call transcripts, but Q2 2026 and Q3 2026 transcripts did not state exact Japan/China unit counts (lacks 3 consecutive latest quarters FY2026Q1–Q3 per Step 5).

Data updated 2026-10-28.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Surgical & Diagnostic Procedures & System Utilization (Key Chính — Core Driver)

Installed Base by Platform, Region & Lease Structure (Key Chính — Core Driver)

System Placements by Platform, Region, Model & Lease Structure (Key Chính — Core Driver)

Unit Economics, Recurring Revenue, Leasing & RPO (Core Driver)

Revenue Disaggregation (Product Category × Geography — U.S. vs. OUS)

Product vs. Service Gross Profit, Non-GAAP Reconciliation & Share-Based Compensation

Working Capital (Inventory by Stage), Lease Receivables, Leased Systems, PP&E & Intangibles

Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return

Environmental Sustainability (Scope 1–3 GHG Inventory), Safety & Workforce Diversity (ESG Reports)

Subsidiaries, Joint Ventures (Intuitive-Fosun China JV), M&A & Litigation

External Regulatory & MedTech Industry Benchmarks (openFDA, ClinicalTrials.gov, FRED)

Consolidated Financial Statements & Product Segment Reference (Postgres DB + FY2026Q3 XBRL)